Clinical Trials Sponsored by Tadashi Watabe

Total 228 results

Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Chronic Kidney Disease

Belarus, Bulgaria, Romania, Malaysia, Singapore, Thailand, Italy, Lithuania, Latvia, Croatia, Denmark, Israel, Indonesia
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

United States, Puerto Rico
Mitsubishi Tanabe Pharma Corporation

Completed

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease

Crohn's Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects

Dyslipidemia

Germany
Mitsubishi Tanabe Pharma Corporation

Completed

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

Coronary Artery Disease | Angina, Unstable

Belgium, Germany
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

Type 2 Diabetes
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

Diabetic Polyneuropathy
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

Peripheral Vascular Disease

United States, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Terminated

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

Peripheral Vascular Disease

United States, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Recruiting

A Study of MT-0551 in Patients With Systemic Sclerosis

Systemic Sclerosis

Japan
Mitsubishi Tanabe Pharma GmbH

Completed

Safety of Argatroban Infusion in Conduction Disturbances (SAICoDis)

Stable Coronary Artery Disease (CAD) | Unstable Angina (Troponin Negative)

Germany
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis

Japanese Patients With ALS

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

Tardive Dyskinesia

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain

Osteoarthritis, Knee / Osteoarthritis, Hip

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
Mitsubishi Tanabe Pharma America

Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

Healthy | Hepatic Impairment

Japan
Mitsubishi Tanabe Pharma America

Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

Healthy | Renal Impairment

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Mitsubishi Tanabe Pharma Corporation

Completed

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

Schizophrenia

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia

Schizophrenia

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Study of Oral Edaravone in Healthy Adult Males

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease

Pediatric Crohn's Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers

Healthy

Netherlands
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

Amyotrophic Lateral Sclerosis (ALS)
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

Plaque Psoriasis | Psoriatic Arthritis | Psoriatic Erythroderma | Pustular Psoriasis (Excluding a Localized)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions

Behcet Syndrome | Behcet's Disease | Neuro-Behcet's Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

Crohn's Disease

France, Israel, Italy, Netherlands, Poland, Slovakia, Ukraine, Czech Republic, Germany, Hungary, Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Extension Study of MT-1303

Relapsing-remitting Multiple Sclerosis

Belgium, Bulgaria, Canada, Croatia, Czech Republic, Finland, Germany, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Perennial Allergic Rhinitis

Japan
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Study of MT-4666 in Subjects With Alzheimer's Disease

Alzheimer's Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Clinical Study of MT-2301

Haemophilus Influenza Type b

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Drug Interaction Study of Warfarin and MT-3995

Healthy

Germany
Mitsubishi Tanabe Pharma Corporation

Terminated

Long-term Extension Study of MCI-196

Chronic Kidney Disease | Hyperphosphatemia | Dialysis | Paediatric

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

Cerebral Infarction
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR

Diabetic Nephropathy

Romania, Bulgaria, Hungary, Poland, Czech Republic, Slovakia
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan

Clinical Trials Sponsored by Tadashi Watabe

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations